Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
29.8 USD | -3.28% | -3.86% | 0.00% |
May. 14 | Goldman Sachs Upgrades CG Oncology to Buy From Neutral With $50 Price Target | MT |
May. 09 | CG Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 2.05B | |
+64.64% | 62.59B | |
-2.05% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+12.86% | 26.21B | |
-21.76% | 19.09B | |
+3.76% | 13.08B | |
+25.54% | 12.26B | |
+27.46% | 12.05B |
- Stock Market
- Equities
- CGON Stock
- News CG Oncology, Inc.
- HC Wainwright Starts Coverage on CG Oncology With Buy Rating, $75 Price Target